Valion Bio Reports Q1 Results, Advances Entolimod Platform

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Valion Bio ( (VBIO) ) has provided an update. On May 14, 2026, Valion Bio reported its first-quarter 2026 results, marking its first full reporting period under the new corporate identity and post-divestiture of its legacy consumer bioelectronics business. During the quarter ended March 31, 2026, the company advanced its Entolimod platform toward potential use as a medical countermeasure and oncology supportive care therapy, broadened engagement with U.S. government agencies, and deepened integration of Velocity Bioworks as both an internal manufacturing engine and an emerging third-party CDMO revenue source. Management highlighted that Entolimod’s differentiated profile and domestic manufacturing footprint are aligning it with national stockpile modernization and allied preparedness priorities, while next-generation TLR5 agonist Entolasta progressed as a platform extension into longevity and immunosenescence. Operating expenses rose to $5.6 million from $1.4 million a year earlier, driving a wider net loss of $6.2 million, as Valion absorbed Velocity Bioworks costs, invested in regulatory and development programs, and incurred one-time rebranding and listing-change expenses, leaving cash of $7.2 million at quarter-end and prompting ongoing evaluation of capital-raising options. Spark’s Take on VBIO Stock According to Spark, TipRanks’ AI Analyst, VBIO is a Neutral. The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data. To see Spark’s full report on VBIO stock, click here. More about Valion Bio Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a clinical-stage immunotherapeutics company developing biologic drugs that activate innate immune pathways for cytoprotection and immune modulation in conditions driven by radiation, disease and immune dysregulation. Its lead candidate, Entolimod, a Toll-like receptor 5 agonist for acute radiation syndrome, is supported by Fast Track and Orphan Drug designations, while its in-house CDMO arm, Velocity Bioworks in San Antonio, targets a structurally underserved U.S. Phase I and II biologics manufacturing market. Average Trading Volume: 307,483 Technical Sentiment Signal: Sell Current Market Cap: $3.45M Learn more about VBIO stock on TipRanks’ Stock Analysis page.